Impact of Blood Count Recovery-based Complete Remission Before Allogeneic Hematopoietic Stem Cell Transplantation on Survival in Patients With Acute Myeloid Leukemia |
| |
| Affiliation: | 1. Antigen Presentation and Immunoregulation Laboratory, Immunology Department, QIMR Berghofer Medical Research Institute, Brisbane, Australia;2. The University of Queensland, Brisbane, Australia;3. Bone Marrow Transplantation Laboratory, Immunology Department, QIMR Berghofer Medical Research Institute, Brisbane, Australia;4. Department of Haematology, Royal Brisbane and Women''s Hospital, Brisbane, Australia;5. School of Biomolecular and Physical Sciences, Griffith University, Nathan, Australia;6. Envoi Pathology, Brisbane, Australia;7. Pediatric Blood and Marrow Transplantation Program, University of Minnesota, Minneapolis, MN;1. Department of Cardiac Surgery, Hôpital Sacré-Coeur de Montréal, Université de Montréal, Québec, Canada;2. Department of Internal Medicine, Hôpital Sacré-Coeur de Montréal, Université de Montréal, Québec, Canada;1. Servicio de Hematología, Hospital Ramón y Cajal, Madrid, España;2. Novartis Oncology, Franquicia de Hematología, San Fernando de Henares, Madrid, España;3. Servicio de Medicina Interna, Hospital Ramón y Cajal, Madrid, España;1. Radiation oncology department, hôpital Saint-Louis, AP–HP, 1, avenue Claude-Vellefaux, 75010 Paris, France;2. Department of haemato-oncology, hôpital Saint-Louis, AP–HP, 1, avenue Claude-Vellefaux, 75010 Paris, France;3. Radiation oncology department, institut Curie, 25, rue d’Ulm, 75005 Paris, France;4. Radiation oncology department, Hartmann Oncology Radiotherapy Group, 4, rue Kléber, CS 90004, 92309 Levallois-Perret cedex, France;1. Division of Hematologic Oncology, Lymphoma Service, Memorial Sloan-Kettering Cancer Center, New York, NY;2. City of Hope Medical Center, Duarte, CA;3. Department of Medicine, Memorial Sloan-Kettering Cancer Center and Weill-Cornell Medical Center, New York, NY;4. GlaxoSmithKline, Oncology Research and Development, Collegeville, PA;5. North Shore University Hospital, New York, NY;6. Johns Hopkins Hospital, Baltimore, MD;7. Columbia University, New York, NY |
| |
| Abstract: | BackgroundPatients who achieve complete remission (CR) with incomplete blood count recovery (CRi) in acute myeloid leukemia (AML) have inferior overall survival and lower progression-free survival. The aim of this study was to define whether blood count recovery-based CR before allogeneic hematopoietic stem cell transplantation (alloHSCT) had an impact on survival in patients with AML.Materials and MethodsThis study has been performed in a retrospective manner. One hundred one patients with AML who received an alloHSCT in our transplant center at Hacettepe University Hospital between the years 2001 and 2018 were evaluated. CRi were defined as bone marrow CR with absolute neutrophil count < 1000/mm3 and/or platelet count < 100.000/mm3. CR and CRi were confirmed just before alloHSCT in bone marrow and peripheral blood, respectively.ResultsA total of 101 patients were entered into the study between 2001 and 2018. Median follow-up for all survivors was 38 months (range, 6-220 months). The 5-year overall survival for patients who were in CRi and patients who were in CR before transplantation were 58% and 67%, respectively (P = .68). The 5-year progression-free survival for patients who were in CRi and patients who were in CR before transplantation were 68% and 64%, respectively (P = .99).ConclusionIn conclusion, we observed equivalent posttransplant outcomes between patients who were in CR and patients who were in CRi before alloHSCT. We assume that alloHSCT eliminated the negative effect of pre-transplant blood count levels. |
| |
| Keywords: | Acute myeloid leukemia AlloHSCT Complete remission Incomplete remission |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
